Press release
Congestive Heart Failure Market to Witness Upsurge in Growth During the Forecast Period 2032, Examine DelveInsight | Key Companies - Novartis, Boehringer Ingelheim and Eli Lilly, Bayer and Merck, AstraZeneca, Amgen, Otsuka Pharmaceutical, Cytokinetics, Me
Congestive Heart Failure Market
DelveInsight's "Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of Congestive Heart Failure, historical and forecasted epidemiology as well as the Congestive Heart Failure market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Congestive Heart Failure Market Report https://www.delveinsight.com/report-store/congestive-heart-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• The Congestive Heart Failure market size was estimated at USD 6,741 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The total prevalent cases of Heart Failure in 2021 in the 7MM were estimated to be 16,630,560 cases
• The highest prevalent cases of this disease seen in the United States were 6,543,570 cases
• In the United States, Congestive Heart Failure diagnosed cases ranges to approximately 550,000 new cases are diagnosed each year
• According to the research, around 1.4 million people who suffer from Congestive Heart Failure are under the age of 60
• In the year 2021, the estimated cases of Congestive Heart Failure were 2,512,731 in males and 2,722,125 in females in the United States
• Key Congestive Heart Failure Companies: Novartis, Boehringer Ingelheim and Eli Lilly, Bayer and Merck, AstraZeneca, Amgen, Otsuka Pharmaceutical, Cytokinetics, Mesoblast, Novo Nordisk, Lexicon Pharmaceuticals, and others
• Key Congestive Heart Failure Therapies: Entresto, Jardiance, Verquvo, Farxiga, Corlanor, Lixivaptan, Irbesartan, KW-3902IV, and others
• The Congestive Heart Failure epidemiology based on gender analyzed that heart failure is an important cause of morbidity and mortality in women, and the patients tend to develop it at an older age compared to men
Request a sample for the Congestive Heart Failure Market Report https://www.delveinsight.com/sample-request/congestive-heart-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Key benefits of the Congestive Heart Failure Market report:
1. Congestive Heart Failure market report covers a descriptive overview and comprehensive insight of the Congestive Heart Failure Epidemiology and Congestive Heart Failure market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Congestive Heart Failure market report provides insights into current and emerging therapies.
3. Congestive Heart Failure market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Congestive Heart Failure market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Congestive Heart Failure market.
Discover more about therapies set to grab major Congestive Heart Failure market share @ Congestive Heart Failure market forecast
https://www.delveinsight.com/sample-request/congestive-heart-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Congestive Heart Failure Overview
Heart Failure (HF) is also known as congestive HF. It is also bifurcated as left-side HF (when the heart is unable to pump enough oxygen in the blood to the body) and right-side HF (when the heart is unable to fill itself with enough blood). Another term for HF is cor pulmonale which means that right-side HF is caused by high blood pressure in the pulmonary arteries and right ventricle. Some people face the problem of HF when the heart has trouble pumping enough blood to support other organs in the body. Some people have a hardening and stiffening of the heart muscle themself, which blocks or reduces blood flow towards the heart. HF initially causes shortness of breath and fatigue (tiredness), and the right side may further cause fluid to build up in the feet, ankles, legs, liver, abdomen, and the veins in the neck.
HF is triggered by structural and functional limitations in the myocardium resulting in damage to ventricular filling or the ejection of blood by the heart. The most common cause of Heart Failure is the lowering of the left ventricular myocardial utility and the dysfunction of the pericardium, myocardium, endocardium, heart valves, or large vessels alone or in combination.
Congestive Heart Failure Symptoms
The Congestive Heart Failure symptoms include -
• Shortness in Breathing while doing any activity or laying down
• Body Fatigue and weakness
• Swelling in the legs, ankles, and feet
• Irregular Heartbeats
• Swelling in the Belly area
Congestive Heart Failure Epidemiology Segmentation:
The Congestive Heart Failure market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Congestive Heart Failure
• Prevalent Cases of Congestive Heart Failure by severity
• Gender-specific Prevalence of Congestive Heart Failure
• Diagnosed Cases of Episodic and Chronic Congestive Heart Failure
Congestive Heart Failure Market
The dynamics of the Congestive Heart Failure market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Jardiance, Verquvo, and others during the forecasted period 2019-2032.
Congestive Heart Failure Market Insights
In August 2021, Boehringer Ingelheim and Eli Lilly announced that the US FDA-approved Jardiance(empagliflozin) 10 mg has reduced the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF)
In February 2021, Novartis announced that the US FDA approved the following expanded indication forEntresto (sacubitril/valsartan): to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal.
Download the report to understand which factors are driving Congestive Heart Failure epidemiology trends @ Congestive Heart Failure Epidemiological Insights
https://www.delveinsight.com/sample-request/congestive-heart-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Congestive Heart Failure Market Drivers
• Robust emerging pipeline
• Recent approval of therapies and promising emerging therapies
• Evidence-based therapies
• Aging of the population
• Rising prevalence of the disease
Congestive Heart Failure Therapies
• Entresto
• Jardiance
• Verquvo
• Farxiga
• Corlanor
• Lixivaptan
• Irbesartan
• KW-3902IV
Congestive Heart Failure Key Companies
• Novartis
• Boehringer Ingelheim and Eli Lilly
• Bayer and Merck
• AstraZeneca
• Amgen
• Otsuka Pharmaceutical
• Cytokinetics
• Mesoblast
• Novo Nordisk
• Lexicon Pharmaceuticals
Scope of the Congestive Heart Failure Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Congestive Heart Failure Companies: Novartis, Boehringer Ingelheim and Eli Lilly, Bayer and Merck, AstraZeneca, Amgen, Otsuka Pharmaceutical, Cytokinetics, Mesoblast, Novo Nordisk, Lexicon Pharmaceuticals, and others
• Key Congestive Heart Failure Therapies: Entresto, Jardiance, Verquvo, Farxiga, Corlanor, Lixivaptan, Irbesartan, KW-3902IV , and others
• Therapeutic Assessment: Congestive Heart Failure current marketed and Congestive Heart Failure emerging therapies
• Migraine Market Dynamics: Congestive Heart Failure market drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Congestive Heart Failure Market Access and Reimbursement
Congestive Heart Failure Market Barriers
• Availability of generic and off-label therapies in the market setting
• Lack of confidence in diagnosis and management
• Treatment failure to stimulate and follow society's goals and requirements
Table of Contents
1. Congestive Heart Failure Market Report Introduction
2. Executive Summary for Congestive Heart Failure
3. SWOT analysis of Congestive Heart Failure
4. Congestive Heart Failure Patient Share (%) Overview at a Glance
5. Congestive Heart Failure Market Overview at a Glance
6. Congestive Heart Failure Disease Background and Overview
7. Congestive Heart Failure Epidemiology and Patient Population
8. Country-Specific Patient Population of Congestive Heart Failure
9. Congestive Heart Failure Current Treatment and Medical Practices
10. Congestive Heart Failure Unmet Needs
11. Congestive Heart Failure Emerging Therapies
12. Congestive Heart Failure Market Outlook
13. Country-Wise Congestive Heart Failure Market Analysis (2019-2032)
14. Congestive Heart Failure Market Access and Reimbursement of Therapies
15. Congestive Heart Failure Market drivers
16. Congestive Heart Failure Market barriers
17. Congestive Heart Failure Appendix
18. Congestive Heart Failure Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Congestive Heart Failure treatment, visit @ Congestive Heart Failure Medications https://www.delveinsight.com/sample-request/congestive-heart-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Related Reports:
Congestive Heart Failure Epidemiology https://www.delveinsight.com/report-store/congestive-heart-failure-chf-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Congestive Heart Failure Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Congestive Heart Failure epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Diagnostic Imaging Equipment Market
https://www.delveinsight.com/report-store/diagnostic-imaging-equipment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.
Invasive Candidiasis Market
https://www.delveinsight.com/report-store/invasive-candidiasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"DelveInsight's 'Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Sialidosis Market
https://www.delveinsight.com/report-store/sialidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology, and the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Filgrastim Biosimilar Insight
https://www.delveinsight.com/report-store/filgrastim-biosimilar-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's, "Filgrastim Biosimilar Insight, 2022," report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Pain Management Devices Market
https://www.delveinsight.com/report-store/pain-management-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027
To know more about our Competitive Services, Click here:
https://www.delveinsight.com/consulting/competitive-intelligence-services?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Congestive Heart Failure Market to Witness Upsurge in Growth During the Forecast Period 2032, Examine DelveInsight | Key Companies - Novartis, Boehringer Ingelheim and Eli Lilly, Bayer and Merck, AstraZeneca, Amgen, Otsuka Pharmaceutical, Cytokinetics, Me here
News-ID: 2718554 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Heart
Heart Healthy Foods and Supplements vs Heart Conditions
Heart conditions remain a major health concern worldwide, but the good news is that specific heart healthy foods and supplements can significantly improve cardiovascular health.
Scientific research has demonstrated that certain foods, nutrients and supplements support heart function, reduce inflammation, and lower the risk of heart disease.
Top Heart Healthy Foods
Fatty Fish - Salmon, mackerel, and sardines are rich in omega-3 fatty acids, which help lower blood pressure and reduce inflammation. A…
Centrifugal Heart Pumps Market | Abbott Laboratories, Abiomed, Berlin Heart, Car …
The global centrifugal heart pumps market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the centrifugal heart pumps market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
Heart disease and Heart Attacks - Kaffailham.gr
Καρδιολόγος Αθηνα - https://kaffailham.gr
When people talk about heart disease or heart attacks. The arteries that they are talking about are the arteries that actually provide blood to the heart. Remember the heart itself is a muscle. It itself needs oxygen. So you have these arteries right over here, the red tubes. Those are arteries. and then the blue ones are veins. They're taking the de-oxygenated blood away from the tissue…
Artificial Heart Implant Market May See a Big Move | Major Giants Jarvik Heart, …
The Latest survey report on Artificial Heart Implant Market sheds lights on changing dynamics of each of the subsegments of Industry. As the shift to value continues, Artificial Heart Implant organizations have the dual challenge of increasing interoperability to improve clinical performance and the patient experience. Some of the companies listed in the study from complete survey list are Medtronic, Boston Scientific, Abbott, Terumo, B.Braun, SynCardia, BiVACOR, CARMAT, ReinHeart TAH…
HEART PUMP DEVICES Market 2020 | SWOT Analysis By Top Players Abbott Laboratorie …
A detailed study on HEART PUMP DEVICES Market formulated by Brandessence Market Research, puts together a concise analysis of the growth factors impacting the current business scenario across assorted regions. Significant information pertaining to the industry's size, share, application, and statistics are also summed in the report in order to present an ensemble prediction. In addition, this report undertakes an accurate competitive analysis illustrating the status of market majors in…
Heart Pump Device Market - Potential Innovations 2025 | Terumo, Jarvik Heart
Heart Pump Device Market: Snapshot
Heart pump devices are essentially mechanical pumps playing the role of ventricular assist devices. These are surgically implanted and are used for temporarily supporting the functions of heart in people with weak heart or irregular blood flow. These devices are notably used as a bridge to cardiac transplantation for patients suffering with end stage heart failure. They can also be used in patients during and after…
